NEW YORK (GenomeWeb News) – SIRS-Lab, a German molecular diagnostic developer, said today that it has begun insolvency proceedings and it is seeking an investor to commercialize its leading product, a test for the causative agent of sepsis.

The company embarked on a clinical trial of Vyoo, its PCR- and array-based sepsis test, in 2011, and said this week that it completed the trial at the end of last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.